GCIA
ALXN

Gabelli & Co Investment Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-189,497
Closed -$34.8M – 581
2021
Q2 		$34.8M Buy
189,497
+34,733
+22% +$5.96M 4.02% 3
2021
Q1 		$23.7M Buy
154,764
+112,214
+264% +$17.4M 2.94% 6
2020
Q4 		$6.65M Buy
+42,550
New +$5.47M 1.04% 24
2019
Q4 		– Sell
-2,250
Closed -$220K – 211
2019
Q3 		$220K Buy
+2,250
New +$254K 0.02% 155

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Gabelli & Co Investment Advisers's ALXN Position: Q3 2021 in Review

Gabelli & Co Investment Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 189,497 shares — an estimated $34.8M sold.

Gabelli & Co Investment Advisers first reported a position in ALXN in Q3 2019 and held it in 4 quarters. The position peaked at $34.8M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Gabelli & Co Investment Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 189,497 Alexion Pharmaceuticals shares in Q3 2021, an estimated $34.8M.
  • Gabelli & Co Investment Advisers first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Gabelli & Co Investment Advisers's Alexion Pharmaceuticals position peaked at $34.8M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.